Adaptive Biotechnologies Finalizes $345M Convertible Notes Offering, Repays OrbiMed Debt
ADPT sits 74% above its 52-week low of $9.955.
Summary
Adaptive Biotechnologies issued $345 million in convertible senior notes, using a significant portion to repay a $156.9 million revenue interest agreement and fund general corporate purposes, while also implementing capped call transactions to manage potential dilution.
Key Events · Financing and Capital Events · ADPT
-
Convertible Notes Issued
The company issued $345 million aggregate principal amount of 0% Convertible Senior Notes due 2031, including the full exercise of the initial purchasers' $45 million option. Net proceeds were approximately $334.5 million.
-
OrbiMed Debt Repaid
Used $156.9 million of the net proceeds to fully repay the OrbiMed Revenue Interest Purchase Agreement, which had a 156% return cap. This terminates a material definitive agreement and improves financial flexibility.
-
Dilution Mitigation via Capped Calls
Entered into capped call transactions for $25.6 million, with a cap price of $34.44 per share (100% premium over the June 16, 2026 closing price of $17.22), designed to reduce potential stock dilution up to that price.
-
Concurrent Share Repurchase
Repurchased 1,451,800 shares of common stock for $25.0 million concurrently with the offering, further mitigating immediate dilution.
Analysis · ADPT · Life Sciences
Adaptive Biotechnologies has completed a significant financing event by issuing $345 million in 0% convertible senior notes. The net proceeds of $334.5 million will be primarily used to repay a $156.9 million revenue interest agreement with OrbiMed, strengthening the company's balance sheet and improving financial flexibility. The offering was priced at a 40% premium to the stock's price on June 16, 2026, and includes capped call transactions to mitigate dilution up to a 100% premium. This capital raise provides substantial funds for general corporate purposes and strategic initiatives in the MRD business, following recent news of evaluating a separation of its immune medicine business.
At the time of this filing, ADPT was trading at $17.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $9.96 to $20.76. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.